摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-乙氧基-3-甲氧基苯基)硼酸 | 1189126-30-4

中文名称
(4-乙氧基-3-甲氧基苯基)硼酸
中文别名
——
英文名称
(4-ethoxy-3-methoxyphenyl)boronic acid
英文别名
——
(4-乙氧基-3-甲氧基苯基)硼酸化学式
CAS
1189126-30-4
化学式
C9H13BO4
mdl
——
分子量
196.011
InChiKey
CXTNPDZQQOJCFP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.23
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    58.9
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2931900090

反应信息

  • 作为反应物:
    描述:
    (4-乙氧基-3-甲氧基苯基)硼酸 、 (R)-4-((R)-1-((6-bromo-3-cyclopropyl-3H-imidazo[4,5-c]pyridin-4-yl)oxy)ethyl)pyrrolidin-2-one 在 四(三苯基膦)钯 、 sodium carbonate 作用下, 以 乙二醇二甲醚 为溶剂, 反应 2.0h, 生成 (R)-4-((R)-1-((3-cyclopropyl-6-(4-ethoxy-3-methoxyphenyl)-3H-imidazo[4,5-c]pyridin-4-yl)oxy)ethyl)pyrrolidin-2-one
    参考文献:
    名称:
    Syk 억제제
    摘要:
    This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
    公开号:
    KR20160037198A
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
    申请人:MEDIVATION TECHNOLOGIES INC
    公开号:WO2015058084A1
    公开(公告)日:2015-04-23
    The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of ΡΒΚδ, and compounds that are dual inhibitors of both Btk and PI3Kδ. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3Kδ provides a therapeutic benefit to a patient having the disease.
    本申请公开了抑制Btk的化合物、抑制ΡΒΚδ的化合物,以及既是Btk又是PI3Kδ的双重抑制剂的化合物。还描述了合成这些抑制剂的方法,以及利用这些抑制剂治疗疾病的方法,其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。
  • TETRAZOLE-CONTAINING 1,2-CYCLOPROPANE-CARBOXAMIDES
    申请人:Bayer Pharma Aktiengesellschaft
    公开号:US20190194148A1
    公开(公告)日:2019-06-27
    The present invention relates to N-(tetrazolylaryl) amide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)所描述和定义的N-(四唑基芳基)酰胺化合物,涉及包含该化合物的药物组合物和配方,以及利用该化合物制造用于治疗或预防疾病的药物组合物,特别是神经源性障碍,作为唯一药剂或与其他活性成分结合使用。
  • SYK INHIBITORS
    申请人:Gilead Sciences, Inc.
    公开号:US20150038488A1
    公开(公告)日:2015-02-05
    The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
    本公开涉及的化合物是Syk抑制剂,并且适用于治疗各种疾病状态,包括癌症和炎症性疾病。在特定实施例中,化合物的结构由公式I给出,其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物,以及使用这些化合物和组合物治疗Syk介导的疾病的方法。
  • Substituted pyrrolidines as SYK inhibitors
    申请人:Gilead Sciences, Inc.
    公开号:US09376441B2
    公开(公告)日:2016-06-28
    The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
    本公开涉及的化合物是Syk抑制剂,用于治疗各种疾病状态,包括癌症和炎症疾病。在特定实施例中,化合物的结构由公式I给出:其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开还提供了含有公式I的化合物或其药学上可接受的盐的药物组合物,以及使用这些化合物和组合物治疗由Syk介导的疾病状态的方法。
  • Syk 억제제
    申请人:GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)
    公开号:KR20160037198A
    公开(公告)日:2016-04-05
    본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.
    This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
查看更多